Delving into the Latest Updates on Sementis Ltd. with Synapse

概览

关联

1

项与 Sementis Ltd. 相关的药物

SCV-ZIKA/CHIK

靶点-

作用机制-

在研机构-

原研机构

QIMR Berghofer Medical Research Institute [+1]

在研适应症-

非在研适应症

基孔肯雅热 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

100 项与 Sementis Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Sementis Ltd. 相关的专利（医药）

登录后查看更多信息

6

项与 Sementis Ltd. 相关的文献（医药）

2018-10-03·Expert Review of Vaccines2区 · 医学

Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines

2区 · 医学

Review

作者: Howley, Paul M. ; Prow, Natalie A. ; Hayball, John D. ; Jimenez Martinez, Rocio ; Suhrbier, Andreas

INTRODUCTIONWith the increasing number of vaccines and vaccine-preventable diseases, the pressure to generate multi-valent and multi-pathogen vaccines grows. Combining individual established vaccines to generate single-shot formulations represents an established path, with significant ensuing public health and cost benefits. Poxvirus-based vector systems have the capacity for large recombinant payloads and have been widely used as platforms for the development of recombinant vaccines encoding multiple antigens, with considerable clinical trials activity and a number of registered and licensed products.AREAS COVEREDHerein we discuss design strategies, production processes, safety issues, regulatory hurdles and clinical trial activities, as well as pertinent new technologies such as systems vaccinology and needle-free delivery. Literature searches used PubMed, Google Scholar and clinical trials registries, with a focus on the recombinant vaccinia-based systems, Modified Vaccinia Ankara and the recently developed Sementis Copenhagen Vector.EXPERT COMMENTARYVaccinia-based platforms show considerable promise for the development of multi-valent and multi-pathogen vaccines, especially with recent developments in vector technologies and manufacturing processes. New methodologies for defining immune correlates and human challenge models may also facilitate bringing such vaccines to market.

Nature Communications1区 · 综合性期刊

A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses

1区 · 综合性期刊

ArticleOA

作者: Diener, Kerrilyn R ; Cooper, Tamara H ; Prow, Natalie A ; Liu, Liang ; Khromykh, Alexander A ; Yan, Kexin ; Hobson-Peters, Jody ; Suhrbier, Andreas ; Eldi, Preethi ; Howley, Paul M ; Tang, Bing ; Le, Thuy T ; Hayball, John D ; Setoh, Yin Xiang ; Nakayama, Eri ; Hazlewood, Jessamine E

AbstractZika and chikungunya viruses have caused major epidemics and are transmitted by Aedes aegypti and/or Aedes albopictus mosquitoes. The “Sementis Copenhagen Vector” (SCV) system is a recently developed vaccinia-based, multiplication-defective, vaccine vector technology that allows manufacture in modified CHO cells. Herein we describe a single-vector construct SCV vaccine that encodes the structural polyprotein cassettes of both Zika and chikungunya viruses from different loci. A single vaccination of mice induces neutralizing antibodies to both viruses in wild-type and IFNAR−/− mice and protects against (i) chikungunya virus viremia and arthritis in wild-type mice, (ii) Zika virus viremia and fetal/placental infection in female IFNAR−/− mice, and (iii) Zika virus viremia and testes infection and pathology in male IFNAR−/− mice. To our knowledge this represents the first single-vector construct, multi-pathogen vaccine encoding large polyproteins, and offers both simplified manufacturing and formulation, and reduced “shot burden” for these often co-circulating arboviruses.

Viruses3区 · 医学

From Crescent to Mature Virion: Vaccinia Virus Assembly and Maturation

3区 · 医学

ReviewOA

作者: Liu, Liang ; Howley, Paul ; Hayball, John ; Cooper, Tamara

Vaccinia virus (VACV) has achieved unprecedented success as a live viral vaccine for smallpox which mitigated eradication of the disease. Vaccinia virus has a complex virion morphology and recent advances have been made to answer some of the key outstanding questions, in particular, the origin and biogenesis of the virion membrane, the transformation from immature virion (IV) to mature virus (MV), and the role of several novel genes, which were previously uncharacterized, but have now been shown to be essential for VACV virion formation. This new knowledge will undoubtedly contribute to the rational design of safe, immunogenic vaccine candidates, or effective antivirals in the future. This review endeavors to provide an update on our current knowledge of the VACV maturation processes with a specific focus on the initiation of VACV replication through to the formation of mature virions.

100 项与 Sementis Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Sementis Ltd. 相关的转化医学

登录后查看更多信息